PIK3CA and neoplasm: Mechanistic investigations indicate that primary drug resistance is primarily attributable to the presence of activating mutations in bypass or downstream signaling pathways within tumor cells, particularly involving the activation of the RAS/MAPK pathway and alterations in the PI3K-AKT pathway (Figure 12) (Zhang Y. et al., 2021).